Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at BTIG Research
Climb Bio (NASDAQ:CLYM – Get Free Report) was upgraded by equities researchers at BTIG Research to a “strong-buy” rating in a report released on Thursday, Marketbeat Ratings reports. The brokerage presently has a $7.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 493.22% from the stock’s previous close. Climb […]
Climb Bio (NASDAQ:CLYM – Get Free Report) was upgraded by equities researchers at BTIG Research to a “strong-buy” rating in a report released on Thursday, Marketbeat Ratings reports. The brokerage presently has a $7.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 493.22% from the stock’s previous close. Climb […]
